[Bone metabolic marker; recent progress].
Measurement of bone markers has been established to supplement measurement of bone mineral density (BMD) in the diagnosis and treatment of osteoporosis. Bone marker provide a clinical useful mean to predict BMD reduction in near future, to assess fracture risk independent of BMD, to select therapeutic regimens for osteoporosis, to assess the effectiveness of drugs much earlier than BMD measurement. On the basis of the findings that a selective estrogen receptor modulator, raloxifene, showed a protective effect of bone fracture far more potent than its BMD-increasing effect, the hypothesis that bone marker indicates fracture risk independent of BMD has been raised and established.